Completed PHASE3 INTERVENTIONAL 2-arm NCT02627963

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Sponsor: AVEO Pharmaceuticals, Inc.

Conditions Carcinoma, Renal Cell

Interventions Sorafenib Tivozanib hydrochloride

Updated 20 times since 2017 Last updated: Jun 27, 2023 Started: May 24, 2016 Primary completion: Oct 4, 2018 Completion: Jun 21, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02627963, this PHASE3 trial focuses on Carcinoma, Renal Cell and remains completed. Sponsored by AVEO Pharmaceuticals, Inc., it has been updated 20 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Aug 2023 — Jul 2024 [monthly]

Completed PHASE3
Feb 2022 — Aug 2023 [monthly]

Completed PHASE3

▶ Show 15 earlier versions

Sep 2021 — Feb 2022 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Apr 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3
Mar 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Mar 2021 [monthly]

Active Not Recruiting PHASE3
Mar 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
Aug 2019 — Mar 2020 [monthly]

Active Not Recruiting PHASE3
Apr 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE3
Sep 2018 — Apr 2019 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE3
Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Sep 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jun 2017 — Sep 2017 [monthly]

Recruiting PHASE3
Mar 2017 — Jun 2017 [monthly]

Recruiting PHASE3
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AVEO Pharmaceuticals, Inc.

Data source: AVEO Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aarhus C, Denmark , Albany, United States , Alcorcón, Spain , Angers, France , Arezzo, Italy , Austin, United States , Aviano, Italy , Badalona, Spain , Barcelona, Spain and 141 more locations